Synonym
ER-34122; ER34122; ER 34122
IUPAC/Chemical Name
Benzamide, 5-((1,5-bis(4-methoxyphenyl)-1H-pyrazol-3-yl)dimethoxymethyl)-2-chloro-
InChi Key
USJVSASRKOHVHQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H26ClN3O5/c1-33-20-10-5-17(6-11-20)24-16-25(30-31(24)19-8-12-21(34-2)13-9-19)27(35-3,36-4)18-7-14-23(28)22(15-18)26(29)32/h5-16H,1-4H3,(H2,29,32)
SMILES Code
O=C(N)C1=CC(C(OC)(C2=NN(C3=CC=C(OC)C=C3)C(C4=CC=C(OC)C=C4)=C2)OC)=CC=C1Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
507.97
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Horizoe T, Nagakura N, Chiba K, Shirota H, Shinoda M, Kobayashi N, Numata H, Okamoto Y, Kobayashi S. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm Res. 1998 Oct;47(10):375-83. doi: 10.1007/s000110050347. PMID: 9831321.
2: Kushida I, Ichikawa M, Asakawa N. Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66. doi: 10.1002/jps.10020. PMID: 11782915.
3: Kushida I, Gotoda M. Investigation for the amorphous state of ER-34122, a dual 5-lipoxygenase/cyclooxygenase inhibitor with poor aqueous solubility, in HPMC solid dispersion prepared by the solvent evaporation method. Drug Dev Ind Pharm. 2013 Oct;39(10):1582-8. doi: 10.3109/03639045.2012.679279. Epub 2012 Apr 20. PMID: 22519663.
4: Horizoe T, Nagakura N, Chiba K, Shirota H, Shinoda M, Numata H, Kobayashi S, Abe C. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice. Inflamm Res. 1999 Aug;48(8):432-6. doi: 10.1007/s000110050483. PMID: 10493160.
5: Kalyoncu NI, Alhan E, Ercin C, Kural BV. Effects of dual inhibitor of cyclooxygenase and 5-lipoxygenase on acute necrotizing pancreatitis in rats. Hepatogastroenterology. 2006 Jul-Aug;53(70):597-602. PMID: 16995470.
6: Ozaki S, Kushida I, Yamashita T, Hasebe T, Shirai O, Kano K. Evaluation of drug supersaturation by thermodynamic and kinetic approaches for the prediction of oral absorbability in amorphous pharmaceuticals. J Pharm Sci. 2012 Nov;101(11):4220-30. doi: 10.1002/jps.23306. Epub 2012 Aug 28. PMID: 22930424.
